NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that physicians at the Mayo Clinic in Jacksonville, Florida, have reported positive outcomes from a large cohort of epilepsy patients treated with the OneRF® Ablation System. The findings, based on real-world clinical use, suggest a potential paradigm shift in the diagnosis-to-therapy pathway for drug-resistant focal epilepsy.
The team, led by neurologist Dr. Brin Freund and the late neurosurgeon Dr. Sanjeet Grewal, performed radiofrequency (RF) ablations on 25 patients with drug-resistant focal epilepsy. Following diagnostic stereo-EEG (SEEG) monitoring with NeuroOne electrodes, the physicians evaluated each patient's seizure foci to determine whether RF ablation could be performed safely. All patients were deemed appropriate candidates based on their anatomy and seizure localization. The physicians evaluated safety, seizure outcomes, and patient-reported quality of life.
The physicians reported that among the 25 evaluable patients, the procedure was well tolerated, with rare short-term effects and no serious long-term complications. The majority of patients experienced meaningful reductions in seizure frequency, while some achieved sustained seizure freedom either directly after the RF ablation or after subsequent surgical or medical therapy guided by data from the ablation. Most patients also reported improved quality of life and satisfaction with the procedure. Ablation targets ranged from small, discrete seizure areas to multifocal or more extensively distributed epileptic networks.
Dr. Freund commented, “NeuroOne SEEG-guided radiofrequency thermocoagulation is a minimally invasive procedure that can be performed at the bedside through the same implanted diagnostic electrodes used to localize a patient's seizures. After recording seizures and mapping critical brain regions responsible for language, motor function, and other essential tasks, we can precisely target seizure-generating tissue while preserving normal brain function. An important advantage of this technology is its ability to deliver a controlled, temperature-based treatment while allowing us to immediately resume recording afterward. This enables us to assess the effectiveness of the ablation in real time and, when appropriate, perform additional targeted ablations during the same monitoring period. This approach has changed how we treat drug-resistant focal epilepsy and is now part of the standard of care at Mayo Clinic Florida.”
“We are extremely grateful to Dr. Freund, the late Dr. Grewal, and the entire Mayo Clinic team for their willingness to evaluate our technology and share their real-world experience,” said Dave Rosa, CEO of NeuroOne. “These results validate our long-held belief that, for patients already undergoing diagnostic SEEG, the ability to potentially deliver meaningful therapeutic benefit through the same implanted electrodes represents a compelling clinical and economic value proposition. Importantly, that opportunity is enabled by our proprietary temperature monitoring technology, which provides physicians with real-time treatment feedback and an additional layer of confidence during ablation. As the only FDA-cleared platform combining SEEG diagnosis and RF ablation using the same sEEG device, we believe NeuroOne is uniquely positioned to support this evolving diagnosis-to-therapy treatment paradigm.”
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. For more information, visit nmtc1.com.
